Illumina

ILLUMINA INC

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

jim cramer chart shutter

News

Markets

Media

Trading Ideas

ACHR

ANET

ILMN

LRCX

PLTR

TSLX

L&#39;esperto di mercato svela le sue strategie: quali titoli premiare e quali abbandonare per navigare con successo il mercato azionario?

Cramer scatenato: cosa comprare, vendere e cosa evitare assolutamente

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

NTLA

OKLO

PATH

Scopri come queste strategie potrebbero influenzare il mercato e cosa riserva il futuro per questi investimenti.

Ecco in quali società sta investendo Cathie Wood tramite Ark

Analyst Color

Long Ideas

Health Care

Analyst Ratings

Tech

General

NVDA

Scopriamo come l&#39;intelligenza artificiale stia rivoluzionando il settore sanitario, con analisi delle opportunità e delle potenziali sfide.

Intelligenza artificiale nella sanità: è la prossima scommessa di Nvidia

Illumina Inc

Illumina Inc COM-WHEN ISSUED

Biotech

Management

Press Releases

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Illumina advances personalized cancer care with new pharma development partnerships

Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

Illumina launches new business to accelerate technology and data-driven discovery

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

4 Diagnostic Stocks Targeting 25%+ Annual Growth in a $20B Market (MDCX, ILMN, EXAS, GH)

ALNY

BSEM

EXAS

MDCX

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO